Lung cancer is the uncontrolled growth of abnormal cells that start off in one or both lungs, usually in the cells that line the air passages.
A recent study, carried out by Cancer Research UK scientists and published in Science, reveals that after the initial genetic fault that causes cancer in the patient, the disease can remain dormant and undetected for a long period of time only to become aggressively active when triggered by additional new genetic mistakes.
The cancer expands when further genetic faults occur in different areas of the tumor. These faults evolve down different paths, leading to a tumor consisting of multiple genetically unique parts.
This discovery explains why targeted treatments are often of limited success. A lung cancer biopsy may identify a specific genetic fault for treatment to target, but in attacking parts of the tumor sharing that particular fault, the areas that share a different genetic mistake are untouched and free to take over.
"Survival from lung cancer remains devastatingly low with many new targeted treatments making a limited impact on the disease," says study author Prof. Charles Swanton. "By understanding how it develops, we've opened up the disease's evolutionary rule book in the hope that we can start to predict its next steps."
According to the Centers for Disease Control and Prevention (CDC), 207,339 people in the US were diagnosed with lung cancer in 2011. A total of 156,953 people died during the same year.
Dr. Noel Snell, director of research at the British Lung Foundation, told Medical News Today why this research is crucial:
"Finding the cancers earlier means that they are more [likely] to be curable; this exciting new research suggests that if they could be diagnosed at a very early stage in their evolution we might be able to tackle the disease earlier and dramatically improve survival rates."
Smoking linked to initial genetic faults
- Lung cancer is the leading cause of cancer death in the US
- Cigarette smoking is the number one cause of lung cancer
- Other risk factors include secondhand smoke, other tobacco products, toxic substances and a family history of lung cancer.
For the study, the team analyzed the lung cancers of seven patients. This group comprised of a mixture of smokers, former smokers and people who had never smoked before.
The study also assessed how smoking impacted on the development of lung cancer, and the researchers found that many of the initial genetic faults leading to lung cancer were caused by smoking..
However, as the cancer grew, these mistakes became less important, with a new process controlled by a protein called APOBEC responsible for creating multiple new mutations.
The team hopes its discovery of cancer lying inactive for several years will lead to improvements in the early detection of the disease. According to Cancer Research UK, less than 10% of lung cancer patients survive for 5 years or more following diagnosis.
Lead scientist for Cancer Research UK, Prof. Nic Jones, is hopeful that their findings can lead to change:
"This fascinating research highlights the need to find better ways to detect lung cancer earlier when it's still following just one evolutionary path. If we can nip the disease in the bud and treat it before it has started traveling down different evolutionary routes, we could make a real difference in helping more people survive the disease."
The organization will attempt to take these findings further by funding a study called TRACERx. This study will analyze the lung cancers of hundreds of patients, observing how they evolve over time. In doing so, they hope to discover precisely how lung cancers adapt, mutate and develop resistance to treatments.
"Late presentation and diagnosis are key reasons for the very poor survival rates from this disease, which are worse in the UK than in Europe and the US," said Dr. Noel Snell. "Greater investment in this sort of research is absolutely vital if we are to make significant advances in the management of this terrible condition."
A recent study unveiled an invention that could identify lung cancer much earlier; a "lab-on-a-chip" could detect lung cancer with just a drop of a patient's blood. Medical News Today reported on the study earlier this week.